Literature DB >> 20859130

Extended resections for thymic malignancies.

Cameron D Wright1.   

Abstract

Almost all series reporting on the results of resection in thymic tumors indicate that the performance of a complete resection is probably the most important prognostic factor. This issue is not a factor in Masaoka stage I and II tumors that are almost always easily completely resected and have an excellent prognosis. Masaoka stage III tumors that invade the pericardium, lungs, or great vessels have relatively higher incomplete resection rates, significantly higher recurrence rates, and thus a worse prognosis. There are several small reports on the efficacy of resection of the great veins when involved by a thymic malignancy with low morbidity and meaningful long-term survival. Superior vena cava reconstruction is commonly performed by a polytetrafluroethylene, venous, or pericardial graft. These cases can usually be identified preoperatively and, thus, considered for induction therapy. Because these types of cases are almost always of marginal respectability in terms of obtaining a true en bloc resection, there is an increasing enthusiasm for offering induction therapy in an effort to enhance resectability. Preliminary results suggest increased R0 resection rates and improved survival with induction therapy for locally advanced tumors. The optimal induction treatment is unknown. The ultimate extended surgery for advanced thymic tumors is an extrapleural pneumonectomy performed for extensive pleural disease (Masaoka stage IVA). These rarely performed operations are done for IVA disease found at initial presentation and for recurrent disease as a salvage procedure. Again these advanced patients are probably best managed by induction chemotherapy followed by resection.

Entities:  

Mesh:

Year:  2010        PMID: 20859130     DOI: 10.1097/JTO.0b013e3181f20eb3

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  12 in total

Review 1.  Surgical management of thymic epithelial tumors.

Authors:  Yasushi Shintani; Soichiro Funaki; Naoko Ose; Takashi Kanou; Eriko Fukui; Kenji Kimura; Masato Minami
Journal:  Surg Today       Date:  2020-07-10       Impact factor: 2.549

2.  Robot-assisted en bloc anterior mediastinal mass excision with pericardium and adjacent lung for locally advanced thymic carcinoma.

Authors:  Hee Chul Yang; Garrett Coyan; Matthew Vercauteren; Neha Reddy; James D Luketich; Inderpal S Sarkaria
Journal:  J Vis Surg       Date:  2018-05-31

3.  Analysis of surgical treatment of Masaoka stage III-IV thymic epithelial tumors.

Authors:  Kazutoshi Hamanaka; Tsutomu Koyama; Shunichiro Matsuoka; Tetsu Takeda; Kentaro Miura; Kyoko Yamada; Akira Hyogotani; Tatsuichiro Seto; Kenji Okada; Ken-Ichi Ito
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-08-21

Review 4.  Neuroendocrine tumors of the thymus: the oncologist point of view.

Authors:  Nicolas Girard
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 5.  [Thymus cancers: A clinical observation].

Authors:  H Grosch; H Hoffmann; C-A Weis; M Thomas
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

6.  Thymoma surgery: extreme surgical indications.

Authors:  Pierluigi Novellis; Giulia Veronesi; Zaheer Raffeeq; Marco Alloisio
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

7.  Extended resections of large thymomas: importance of en bloc thymectomy.

Authors:  José Francisco Corona-Cruz; Raúl Alejandro López-Saucedo; Laura Alejandra Ramírez-Tirado; Delia Pérez-Montiel; Josué Andrés González-Luna; Edgardo Jiménez-Fuentes; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

8.  Radical surgical resection of advanced thymoma and thymic carcinoma infiltrating the heart or great vessels with cardiopulmonary bypass support.

Authors:  Michael Ried; Reiner Neu; Berthold Schalke; Marietta von Süßkind-Schwendi; Zsolt Sziklavari; Hans-Stefan Hofmann
Journal:  J Cardiothorac Surg       Date:  2015-10-29       Impact factor: 1.637

9.  Stage-related outcome for thymic epithelial tumours.

Authors:  Valentina Tassi; Jacopo Vannucci; Silvia Ceccarelli; Alessio Gili; Alberto Matricardi; Nicola Avenia; Francesco Puma
Journal:  BMC Surg       Date:  2019-04-24       Impact factor: 2.102

10.  A single-center experience: management of patients with thymic epithelial tumors.

Authors:  Marius Kemper; Mona Moradzadeh; Eugen Bellon; Ahmad S Bahar; Rainer Grotelüschen; Matthias Reeh; Jakob R Izbicki; Kai Bachmann
Journal:  World J Surg Oncol       Date:  2020-08-13       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.